Eton Pharmaceuticals Inc. Common Stock (ETON)

FairStock Score: 50/100 — MIXED

Key Financials

Strengths

• Generates $11 million in annual free cash flow (1.8% yield on market cap)
• Altman Z-Score of 4.7 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 82.7% demonstrates strong top-line momentum

AI Analysis

Eton Pharmaceuticals Inc. Common Stock is a micro-cap healthcare company valued at $634 million. The business generates $80 million in annual revenue with a 1.9% net margin and $11 million in free cash flow. From a quality standpoint, Eton shows healthy Altman Z-Score of 4.7 and negative ROE indicating losses. Growth dynamics show revenue growing at 82.7% and profit growth of 348.0%. Our composite FairStock Score of 50/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Eton's 83% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $11 million in annual free cash flow (1.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer